Full history for every metric is available with a Kvantra account
Silk Road Medical, Inc (SILK)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 35 | 63 | 75 | 101 | 139 | 177 | 191 |
| Operating profit | $m | -59 | -60 | |||||
| Net profit | $m | -38 | -56 | -50 | -50 | -58 | -56 | -57 |
| EPS reported | $ | -1.44 | -1.44 | |||||
| Operating cashflow per share | $ | -0.83 | -0.83 | |||||
| Capex per share | $ | 0.04 | 0.04 | |||||
| FCF per share | $ | -0.86 | -0.86 | |||||
| Free cash flow | $m | -34 | -36 | |||||
| Net debt | $m | -99 | -94 | |||||
| Book value equity | $m | 151 | 155 | |||||
| Book value per share | $ | 3.90 | 3.90 | |||||
| Number of shares | m | 38.8 | 39.62 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 3.15 | 7.22 | |||||
| P/S LTM | x | 2.69 | 5.83 | |||||
| P/FCF LTM | x | -14.20 | -30.95 | |||||
| EV/EBITDA LTM | x | -11.99 | -22.29 | |||||
| EV/Sales LTM | x | 3.05 | 5.34 | |||||
| Earnings Yield LTM | % | -11.71% | -5.23% | |||||
| FCF Yield | % | -7.04% | -3.23% | |||||
| Quality | ||||||||
| ROE | % | -36.88% | -35.39% | |||||
| ROIC | % | -25.04% | -25.04% | |||||
| Operating margin | % | -33.46% | -33.46% | |||||
| Gross margin | % | 71.75% | 71.75% | |||||
| FCF/Sales | % | -18.92% | -18.92% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +27.77% | +17.53% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.40 | -0.43 | |||||
| Net Debt/EBITDA | x | -1.43 | -1.43 | |||||
| EBIT/Net interest | x | -8.63 | -8.63 | |||||
| Net debt/market cap | % | -20.70% | -8.42% | |||||
| Net debt/Equity | x | -0.65 | -0.61 | |||||
| Gross debt/equity | x | 0.56 | 0.55 | |||||
Company overview
Silk Road Medical, Inc. operates as an American medical device company, focusing on innovative solutions for carotid artery disease. The firm's product portfolio is specifically engineered to support transcarotid artery revascularization (TCAR) procedures. Among its key offerings is the ENROUTE Transcarotid Neuroprotection System, designed to directly access the common carotid artery and initiate a temporary reversal of blood flow. The company also provides the ENROUTE Transcarotid Stent System, a distinctive stent characterized by its self-expanding and self-tapering capabilities. For streamlined initial entry to the common carotid artery, Silk Road Medical offers the ENHANCE Transcarotid Peripheral Access Kit. Additionally, the ENROUTE 0.014 Guidewire plays a crucial role in navigating and crossing target lesions, enabling the precise delivery of other interventional devices. Founded in 2007, Silk Road Medical, Inc. maintains its primary corporate offices in Sunnyvale, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Silk Road Medical, Inc (SILK)
Silk Road Medical, Inc. operates as an American medical device company, focusing on innovative solutions for carotid artery disease. The firm's product portfolio is specifically engineered to support transcarotid artery revascularization (TCAR) procedures. Among its key offerings is the ENROUTE Transcarotid Neuroprotection System, designed to directly access the common carotid artery and initiate a temporary reversal of blood flow. The company also provides the ENROUTE Transcarotid Stent System, a distinctive stent characterized by its self-expanding and self-tapering capabilities. For streamlined initial entry to the common carotid artery, Silk Road Medical offers the ENHANCE Transcarotid Peripheral Access Kit. Additionally, the ENROUTE 0.014 Guidewire plays a crucial role in navigating and crossing target lesions, enabling the precise delivery of other interventional devices. Founded in 2007, Silk Road Medical, Inc. maintains its primary corporate offices in Sunnyvale, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free